Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.59 |
| ▸ | FLT4 | P35916 | 4/20 | 0.59 |
| ▸ | FLT3 | P36888 | 4/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | KIF5B | P33176 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455398 | 0.86 | PDGFRB (0.64) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL4023315 | 0.85 | PDGFRB (0.75) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL8204598 | 0.82 | CSF1R (0.47) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL13680204 | 0.81 | KDR (0.73) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL7452950 | 0.81 | PDGFRB (0.66) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL4359665 | 0.80 | CSF1R (0.81) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL18158553 | 0.79 | KDR (0.70) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL23158591 | 0.78 | CSF1R (0.66) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL30406755 | 0.78 | CSF1R (0.68) | CSF1RPDGFRBFLT4FLT3EGFR | |
| SCHEMBL4466873 | 0.78 | CSF1R (0.68) | CSF1RPDGFRBFLT4FLT3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | CSF1R 118/4885PDGFRB 119/4885FLT4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.